If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non-small cell lung cancer

$48.00 plus tax (Refund Policy)

Download / Buy Article:

Abstract:

Abstract Background:

We report a study of induction chemotherapy followed by concurrent chemoradiotherapy for stage IIIA/IIIB non-small cell lung cancer. Methods:

Patients received two cycles of induction chemotherapy with cisplatin 100 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8, and 15 of a 28‐day cycle. If the disease was unresectable, surgery was followed with two further cycles. If unresectable, patients received cisplatin 100 mg/m2 day 1, 29 with 5‐fluorouracil 1000 mg/m2 per 24 h continuous infusion for 96 h on days 2–5 and days 30–33 of the radiotherapy administration. Radiation therapy consisted of 63 Gy, 35 fractions, 7 weeks. Results:

Of 48 patients, 40% had a partial response to induction chemotherapy. Four of eleven patients with stage IIIA tumours had resectable disease. The remaining seven patients plus 37 with stage IIIB disease had chemoradiotherapy. Response at the completion of all therapy was 62% (IIIA 73%, IIIB 59%). For all patients the median survival was 15.3 months: 1 year and 3 years, 58% and 25%, respectively. Those with IIIB disease responding to induction chemotherapy had significantly superior survival to those that did not respond (37 months vs 11 months; P = 0.005). This remained significant from a landmark at 8 weeks after the start of treatment (P = 0.01). Conclusion:

These results are equivalent to other studies using induction chemotherapy prior to concurrent chemoradiotherapy. Response to induction chemotherapy may have major prognostic significance. (Intern Med J 2005; 35: 336–342)

Keywords: chemotherapy; clinical trial; lung cancer; radiotherapy; stage III

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1445-5994.2005.00837.x

Affiliations: 1: Medical Oncology 2: Respiratory Medicine 3: Radiation Oncology 4: Cardiothoracic Surgery, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

Publication date: June 1, 2005

Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more